Sei Investments Co. Has $3.54 Million Stock Position in Certara, Inc. $CERT

Sei Investments Co. reduced its holdings in Certara, Inc. (NASDAQ:CERT) by 43.6% in the 1st quarter, Holdings Channel reports. The fund owned 620,967 shares of the company’s stock after selling 479,880 shares during the period. Sei Investments Co.’s holdings in Certara were worth $3,540,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of CERT. Northwestern Mutual Wealth Management Co. grew its stake in Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after acquiring an additional 2,870 shares in the last quarter. Osaic Holdings Inc. increased its holdings in shares of Certara by 50.7% in the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after purchasing an additional 1,175 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Certara by 499.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,917 shares of the company’s stock worth $69,000 after purchasing an additional 4,930 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of Certara in the second quarter worth approximately $83,000. Finally, Gamco Investors INC. ET AL acquired a new stake in shares of Certara during the fourth quarter worth approximately $90,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have weighed in on CERT shares. Morgan Stanley dropped their price objective on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. BMO Capital Markets decreased their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a report on Wednesday. Barclays upped their price target on shares of Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a research note on Wednesday. Finally, KeyCorp reduced their price objective on Certara from $10.00 to $8.00 and set an “overweight” rating for the company in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Certara currently has an average rating of “Hold” and a consensus target price of $8.28.

Certara Stock Performance

CERT stock opened at $8.13 on Friday. The company has a quick ratio of 1.88, a current ratio of 2.55 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -18.07 and a beta of 1.44. Certara, Inc. has a 12 month low of $4.45 and a 12 month high of $13.88. The firm has a 50 day moving average of $6.52 and a two-hundred day moving average of $6.54.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The business’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.07 EPS. As a group, equities analysts anticipate that Certara, Inc. will post 0.24 EPS for the current fiscal year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.